BofA raises Amylyx Pharmaceuticals stock price target on model updates

BofA Securities raised Amylyx Pharmaceuticals’ price target to $22 from $19 and kept a Buy rating, citing a lower 10% discount rate, improved avexitide assumptions, and a $1.8 billion peak sales forecast. The firm also flagged a key Q3 avexitide clinical catalyst and updated its model for a $4 million AMX0318 milestone payment and ongoing trial costs, with 2026 R&D now expected to tick higher. Recent EPS of -0.30 beat the -0.34 estimate by 11.76%, reinforcing a constructive but still speculative outlook.

Analysis

AMLX is increasingly being valued like a binary clinical readout with a cash cushion, not like a traditional commercial biotech. The market is implicitly assigning meaningful probability to avexitide success while discounting the near-term burn, and that combination can keep the stock bid even if operating expenses drift higher. The second-order effect is that every incremental de-risking event tightens the equity financing overhang, which is worth more than the headline price target move because it reduces dilution risk into the catalyst window.

The real sensitivity is not the small change in expense guidance; it is whether the third-quarter catalyst confirms a program large enough to support a multi-bagger rerating. If avexitide data are clean, the stock can re-rate well beyond current targets because the market is still likely underweight the value of a credible obesity-adjacent rare-disease asset with partnerable economics. If the signal is merely acceptable rather than transformative, the current valuation can compress quickly since the recent run has already pulled forward a lot of optionality.

Consensus may be missing that the best risk/reward is probably not a straight equity long into the event, but owning convexity while limiting downside. The name has already outperformed enough that the easy money is gone; the remaining upside depends on a discrete clinical dataset, while downside is cushioned only by cash and sentiment, both of which can be fragile if timelines slip. The key contrarian point: upgraded price targets can actually be a late-cycle tell when multiple analysts are converging on the same catalyst narrative.

Secondary winners are likely small-cap biotech peers with near-term rare-disease readouts, because a strong AMLX result would reinforce investor appetite for platform stories and higher terminal value assumptions across the group. Losers would be other pre-revenue names with similar burn profiles but weaker cash positions, as capital may rotate toward names with cleaner balance sheets and clear event windows.

Key Decisions for Investors

• Buy AMLX call spreads into the Q3 avexitide catalyst, ideally 60-90 days before the readout; structure for 2-3x upside if the data de-risk peak-sales assumptions while capping premium burn if timing slips.
• If already long common, reduce into strength above the latest target cluster and re-enter only on post-catalyst volatility; the stock has likely already priced in a meaningful fraction of the favorable analyst revision cycle.
• Pair trade: long AMLX / short a basket of cash-poor, preclinical biotech names over the next 1-2 quarters; the balance-sheet differential should matter more if risk capital stays selective.
• Use any post-data gap-up above consensus valuation bands to monetize 25-50% of the position; the best-case rerating is large, but the probability-weighted payoff declines sharply after a clean initial move.
• For event traders, consider a calendar structure that owns the third-quarter catalyst and sells shorter-dated upside into analyst-upgrade momentum; this captures the pre-readout drift while limiting exposure to a disappointing binary print.